Division of Infectious Diseases and International Health, Department of Medicine, and.
Clinical Microbiology Laboratory, Department of Pathology, Duke University Medical Center, Durham, North Carolina.
Clin Infect Dis. 2017 Jun 1;64(11):1619-1621. doi: 10.1093/cid/cix130.
Breakthrough invasive mold infections (IMIs) that occur during posaconazole or voriconazole prophylaxis are rare complications for which epidemiological data are lacking. This retrospective analysis comparing 24 microbiologically documented breakthrough with 66 nonbreakthrough IMIs shows a shift towards non-Aspergillus molds with a significantly increased proportion of rare multidrug-resistant molds.
突破性侵袭性霉菌感染（IMI）在泊沙康唑或伏立康唑预防期间发生较为罕见，但缺乏相关的流行病学数据。本回顾性分析比较了 24 例微生物学确诊的突破性感染和 66 例非突破性 IMI，结果显示非曲霉属霉菌的比例明显增加，且耐药性罕见的多药耐药霉菌显著增加。
